newsfilter
← Latest News
Business Wire·

Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

-- QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein, Progresses in Preclinical Development for the Treatment of Hereditary Angioedema -- -- Strong Cash Position of $146.9M Planned to Fund IND-Enabling Studies, P